RxDoctor Payments Data

Kelly Wimberly, MD

Family Medicine · Dallas, TXNPI 1053330803

Payments from drug & device makers

$10,335in general payments, 2019–2025

Across 486 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Amgen$841
  • Lilly USA, LLC$522
  • Boehringer Ingelheim$460
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$10,290100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,335 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$189,970
Medicare patients
317
Services billed
2,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide66$84,913
OzempicSemaglutide46$50,283
FarxigaDapagliflozin Propanediol43$33,089
RybelsusSemaglutide19$26,794
JanuviaSitagliptin Phosphate13$14,686
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$13,056
ShingrixVaricella-Zoster Ge/As01b/Pf47$10,488
EliquisApixaban11$6,395
SynthroidLevothyroxine Sodium59$4,185
Boostrix TdapDiphth,pertuss(Acell),tet Vac43$3,010
Levothyroxine Sodium318$2,722
Atorvastatin Calcium333$2,522
Rosuvastatin Calcium153$2,020
Omeprazole111$1,603
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide45$1,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$522$84,91366 claims
Novo NordiskOzempic, Rybelsus$1,324$77,07765 claims
AstraZenecaFarxiga$1,622$33,08943 claims
MerckJanuvia$329$14,68613 claims
GSKShingrix$140$10,48847 claims
PfizerEliquis$412$6,39511 claims
AbbVieSynthroid$1,126$4,18559 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →